Maisenbacher Melissa K, Merrion Katrina, Pettersen Barbara, Young Michael, Paik Kiyoung, Iyengar Sushma, Kareht Stephanie, Sigurjonsson Styrmir, Demko Zachary P, Martin Kimberly A
Natera, Inc., 201 Industrial Road, San Carlos, 94070 CA USA.
Mol Cytogenet. 2017 Mar 9;10:6. doi: 10.1186/s13039-017-0308-6. eCollection 2017.
The 22q11.2 deletion syndrome is the most common microdeletion syndrome in livebirths, but data regarding its incidence in other populations is limited and also include ascertainment bias. This study was designed to determine the incidence of the 22q11.2 deletion in miscarriage samples sent for clinical molecular cytogenetic testing.
Twenty-six thousand one hundred one fresh product of conception (POC) samples were sent to a CLIA- certified, CAP-accredited laboratory from April 2010--May 2016 for molecular cytogenetic miscarriage testing using a single-nucleotide polymorphism (SNP)-based microarray platform. A retrospective review determined the incidence of the 22q11.2 deletion in this sample set. Fetal results were obtained in 22,451 (86%) cases, of which, 15 (0.07%) had a microdeletion in the 22q11.2 region (incidence, 1/1497). Of those, 12 (80%) cases were found in samples that were normal at the resolution of traditional karyotyping (i.e., had no chromosome abnormalities above 10 Mb in size) and three (20%) cases had additional findings (Trisomy 15, Trisomy 16, XXY). Ten (67%) cases with a 22q11.2 deletion had the common ~3 Mb deletion; the remaining 5 cases had deletions ranging in size from 0.65 to 1.5 Mb. A majority (12/15) of cases had a deletion on the maternally inherited chromosome. No significant relationship between maternal age and presence of a fetal 22q11.2 deletion was observed.
The observed incidence of 1/1497 for the 22q11.2 deletion in miscarriage samples is higher than the reported general population prevalence (1/4000-1/6000). Further research is needed to determine whether the 22q11.2 deletion is a causal factor for miscarriage.
22q11.2缺失综合征是活产儿中最常见的微缺失综合征,但关于其在其他人群中的发病率数据有限,且存在确诊偏倚。本研究旨在确定送检临床分子细胞遗传学检测的流产样本中22q11.2缺失的发生率。
2010年4月至2016年5月期间,26101份新鲜的妊娠产物(POC)样本被送往一家经CLIA认证、CAP认可的实验室,使用基于单核苷酸多态性(SNP)的微阵列平台进行分子细胞遗传学流产检测。通过回顾性分析确定该样本组中22q11.2缺失的发生率。22451例(86%)获得了胎儿检测结果,其中15例(0.07%)在22q11.2区域存在微缺失(发生率为1/1497)。其中,12例(80%)在传统核型分析分辨率下正常的样本中被发现(即没有大于10 Mb大小的染色体异常),3例(20%)有其他发现(15三体、16三体、XXY)。10例(67%)22q11.2缺失病例有常见的约3 Mb缺失;其余5例缺失大小在0.65至1.5 Mb之间。大多数(12/15)病例的母系遗传染色体上存在缺失。未观察到母亲年龄与胎儿22q11.2缺失之间存在显著关系。
流产样本中观察到的22q11.2缺失发生率为1/1497,高于报道的一般人群患病率(1/4000 - 1/6000)。需要进一步研究以确定22q11.2缺失是否为流产的致病因素。